Clinical trial
A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma
NCT00372853 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma
- Lead sponsor
- AstraZeneca
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- May 31, 2010
- Enrollment
- 28 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.